Stoke Therapeutics (STOK) Current Deferred Revenue (2022 - 2026)
Stoke Therapeutics (STOK) posted quarterly Current Deferred Revenue of $10.1 million for Q1 2026, down 44.58% year-over-year from $18.2 million in Q1 2025, and down 15.42% quarter-over-quarter from $11.9 million in Q4 2025.
Stoke Therapeutics (STOK) Current Deferred Revenue (2022 - 2026) Analysis & Trends
Stoke Therapeutics' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $10.1 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 44.58% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $10.1 million (down 44.58% YoY), while the FY2025 annual figure was $11.9 million, down 37.33% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $10.1 million, down from $11.9 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $31.6 million in Q3 2024, with the low at $5.8 million in Q3 2025.
- The 5-year median for Current Deferred Revenue is $12.8 million (2022), against an average of $14.4 million.
- The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue soared 261.9% in 2024, then slumped 81.77% in 2025.
- Stoke Therapeutics' Current Deferred Revenue stood at $14.9 million in 2022, then gained by 2.88% to $15.3 million in 2023, then gained by 24.05% to $19.0 million in 2024, then plunged by 37.33% to $11.9 million in 2025, then retreated by 15.42% to $10.1 million in 2026.
- Business Quant data shows STOK's Current Deferred Revenue at $10.1 million in Q1 2026, $11.9 million in Q4 2025, and $5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.52 Mn |
| Mar 31, 2026 | 10.07 Mn |
| Dec 31, 2025 | 11.90 Mn |
| Sep 30, 2025 | 5.76 Mn |
| Jun 30, 2025 | 8.75 Mn |
| Mar 31, 2025 | 18.16 Mn |
| Dec 31, 2024 | 18.99 Mn |
| Sep 30, 2024 | 31.61 Mn |
| Jun 30, 2024 | 26.05 Mn |
| Mar 31, 2024 | 20.92 Mn |
| Dec 31, 2023 | 15.31 Mn |
| Sep 30, 2023 | 8.74 Mn |
| Jun 30, 2023 | 8.06 Mn |
| Mar 31, 2023 | 13.45 Mn |
| Dec 31, 2022 | 14.88 Mn |
| Sep 30, 2022 | 12.84 Mn |
| Jun 30, 2022 | 10.63 Mn |
| Mar 31, 2022 | 8.47 Mn |